Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trialRichard Furie, Raj Tummala, Theresa Lawrence Ford et al.|The Lancet Rheumatology|2019Cited by 478
European consensus statement on the terminology used in the management of lupus glomerulonephritisCaroline Gordon, G. R. V. Hughes, David Jayne et al.|Lupus|2009Cited by 150
ContributorsFrederick W. Alt, Hiroyuki Marusawa, Radbruch Andreas et al.|Elsevier eBooks|2014Cited by 0